# Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease

* Behçet’s disease is more prevalent in countries along the Silk Road, including Türkiye, Iran and Japan.
* Even with treatment, symptoms can continue occurring for many patients and significantly affect their quality of life and productivity.
* Soligenix has initiated a clinical trial to evaluate the safety, tolerability and preliminary efficacy of SGX945 in patients suffering from oral ulcers.

 Behçet’s disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to a range of symptoms including painful mouth and genital ulcers, eye inflammation and skin lesions. With limited treatment options available, Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies, notably SGX945 (dusquetide), aiming to address the unmet need in this challenging disease landscape (https://ibn.fm/KByRu).

 Behçet’s disease is rare, with prevalence estimates varying from 0.12 to 7.5 per 100,000 in the United States and Europe. It’s more prevalent in countries along the Silk Road, including Türkiye, Iran, and Japan. In Türkiye, prevalence can range from 80 to 370 per 100,000. Symptoms of the disease include…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-makes-advancement-in-proprietary-treatment-for-behcets-disease/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-advances-treatment-for-behcets-disease-with-sgx945/08951920fccb8a3fa1b9d09e41b98cf6) 

 



[Reddit Post](https://www.reddit.com/r/technology_press/comments/1ldqk20/soligenix_advances_treatment_for_behçets_disease/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/256/17/daveBDje.webp)